A detailed history of Avantax Advisory Services, Inc. transactions in Incyte Corp stock. As of the latest transaction made, Avantax Advisory Services, Inc. holds 7,500 shares of INCY stock, worth $522,224. This represents 0.0% of its overall portfolio holdings.

Number of Shares
7,500
Previous 7,586 1.13%
Holding current value
$522,224
Previous $459,000 7.84%
% of portfolio
0.0%
Previous 0.0%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$57.33 - $68.61 $4,930 - $5,900
-86 Reduced 1.13%
7,500 $495,000
Q2 2024

Aug 09, 2024

BUY
$51.18 - $63.75 $159,630 - $198,836
3,119 Added 69.82%
7,586 $459,000
Q1 2024

May 08, 2024

BUY
$56.55 - $66.59 $252,608 - $297,457
4,467 New
4,467 $254,000

Others Institutions Holding INCY

About INCYTE CORP


  • Ticker INCY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 222,431,008
  • Market Cap $15.5B
  • Description
  • Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...
More about INCY
Track This Portfolio

Track Avantax Advisory Services, Inc. Portfolio

Follow Avantax Advisory Services, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Avantax Advisory Services, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Avantax Advisory Services, Inc. with notifications on news.